Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 1, Pages 85-91
Publisher
Springer Nature
Online
2011-11-30
DOI
10.1038/bjc.2011.514
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vitro studies of dasatinib, its targets and predictors of sensitivity
- (2011) Lucia B. Jilaveanu et al. Pigment Cell & Melanoma Research
- Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
- (2010) D Handolias et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase 2 trial of dasatinib in advanced melanoma
- (2010) Harriet M. Kluger et al. CANCER
- Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically.
- (2010) Liam Morgan et al. CANCER BIOLOGY & THERAPY
- Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo
- (2010) Cara K. Fraser et al. CANCER BIOLOGY & THERAPY
- CAV1 Inhibits Metastatic Potential in Melanomas through Suppression of the Integrin/Src/FAK Signaling Pathway
- (2010) C. Trimmer et al. CANCER RESEARCH
- 254 cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines
- (2010) F. Journe et al. EJC SUPPLEMENTS
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-κB
- (2010) H Boukerche et al. ONCOGENE
- Episodic Src activation in uveal melanoma revealed by kinase activity profiling
- (2009) W Maat et al. BRITISH JOURNAL OF CANCER
- Caveolin-1 tumor-promoting role in human melanoma
- (2009) Federica Felicetti et al. INTERNATIONAL JOURNAL OF CANCER
- Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma
- (2009) Jade Homsi et al. MELANOMA RESEARCH
- Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type
- (2009) Carlos A Torres-Cabala et al. MODERN PATHOLOGY
- Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
- (2009) S. E. Woodman et al. MOLECULAR CANCER THERAPEUTICS
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
- (2008) I Satzger et al. BRITISH JOURNAL OF CANCER
- KIT Gene Mutations and Copy Number in Melanoma Subtypes
- (2008) C. Beadling et al. CLINICAL CANCER RESEARCH
- Src kinase induces tumor formation in the c-SRC C57BL/6 mouse
- (2008) Christina Leah B. Kline et al. INTERNATIONAL JOURNAL OF CANCER
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- (2008) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
- (2008) Alex J Eustace et al. Journal of Translational Medicine
- Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
- (2008) R. Buettner et al. MOLECULAR CANCER RESEARCH
- Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
- (2008) Jose Lutzky et al. Pigment Cell & Melanoma Research
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started